Executive search firm Toft Group has placed Timothy E. Cooley as Vice President, Information Technology at Synthetic Genomics, Inc. (SGI), in La Jolla, CA.
Mr. Cooley has many years of experience in leading information technology in life sciences companies. He has previously served as Director of Business Solutions for MPI Research, Executive Vice President of US Operations at Molecular Health, and CIO for NAMSA. He also volunteers as Chief Data Officer for the Human Health Project. Earlier in his industry career Mr. Cooley spent 15 years with Eli Lilly where he held several roles, most recently as their Director of Information Technology, Medical and Health Outcomes. Mr. Cooley holds a BS in Microbiology from Texas A&M University
About Toft Group Executive Search
Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.
About Synthetic Genomics, Inc.
Synthetic Genomics, Inc. (SGI) is a private biotechnology company harnessing the power of living cells — nature’s most efficient machines — to create transformative medicines and bio-based products. With an unmatched understanding of how DNA and RNA instruct the functions of life, we program cells for improved purpose and function. Our R&D competencies focus on our novel self-amplifying RNA replicon platform for infectious disease and oncology vaccines and therapeutics and our algal cell systems for industrial and biotherapeutic discovery and manufacturing. Built on a legacy of scientific firsts, our team of biological engineers are shaping the future bioeconomy.